Observational studyPloS one2026
Modelling Hepatitis B virus related hospital discharges in Spain: ARIMAX based liver disease forecasting tool for hospital workload and mortality progression.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic hepatitis B (CHB) virus infection leads to severe complications, cirrhosis and hepatocellular carcinoma (HCC). The main objective of this study was to develop an ARIMA-based model to forecast the progression of global hospital discharges, due to cirrhosis and HCC related to chronic hepatitis B.
methodsRetrospective observational study of monthly incidence of CHB related hospitalization discharges from 2005 to 2021 in Spain. Data were obtained through the Spanish Minimum dataset of hospital discharge registry (CMBDH) of the Health Ministry. Main diagnosis of CHB, liver cirrhosis and HCC encoded by International Medical codes (ICM-9 and ICM-10) were used. Descriptive and time series analysis was performed with forecasts made for 2022 using seasonal ARIMA and ARIMAX models. Data stationarity was achieved via a square root Box-Cox transformations and differencing. Model selection used was AIC, BIC, MAPE, and forecasting precision. Analysis was performed in R (version 4.5.0).
resultsThe total number of discharges related to hepatitis B was 6743, 58% were due to HCC and 42% to cirrhosis diagnosis. Median age was 59 years (range: 7 to > 100), being 83.4% men. The global chronic hepatitis B (CHB) related workload values range from 10 to 55 monthly discharges, while hepatitis B related to HCC and cirrhosis range from 4 to 34 and 1-29 discharges, respectively. The best fit and 2022 forecasts found for CHB and HCC time series was obtained with the approximate Gaussian [Formula: see text]-ARIMAX (6,0,0) (0,1,1) _12 model. This model after treating outliers, removes seasonal patterns and captures the series' autoregressive dynamics with an AR(6) and seasonal MA(1) noise with expression: [Formula: see text] with ε ~ N(0, σ²) and in the square root scale.
conclusionBoth ARIMA and ARIMAX models play critical roles in forecasting CHB-related HCC and cirrhosis, enabling better disease monitoring, healthcare resources, and intervention assessment. ARIMAX provided more accurate context-aware predictions, making it especially valuable for public health decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.